Key clinical point: The novel targeted cancer therapies cause markedly fewer cardiac arrhythmias.
Major finding: Cancer patients treated with a tyrosine kinase inhibitor, immune checkpoint inhibitor, or another of the novel targeted therapies were 40% less likely than were those on anthracycline-based therapy to develop a treatment-induced cardiac arrhythmia up to 6 months after treatment initiation.
Study details: This was a retrospective single-center study including more than 5,000 cancer patients.
Disclosures: The presenter reported having no financial conflicts regarding his study, which was conducted free of commercial support.
Source: Nickel A et al. ACC 18, Abstract #900-06.
Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.
This Week's Must Reads
Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7
CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P
Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.
New guidelines from the UK on chronic lymphocytic leukemia, Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460
JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.
Must Reads in Thrombosis
Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.
Poor adherence to DOAC therapy requires attention, Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.
Sepsis-related coagulopathy and in-hospital death risk, Lyons PG et al. Crit Care Med. 2018 May;46(5):73642.
New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.
Increase kidney function monitoring if INR exceeds 4.0, Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.